A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
BUSINESS
FY2016 Earnings Roundup - 5: Drug Makers Anticipate Nearly Flat Growth in FY2017; Mid-Term Outlook Unclear
By Reiji Anasako What changes can research-oriented drug makers expect to see in FY2017? They’re hoping for growth in sales of global products in overseas markets, but in Japan they will face a number of negative factors such as the…
To read the full story
Related Article
- FY2016 Earnings Roundup - 4: Average Productivity per Sales Rep Up Only 14 Million Yen in 6 Years
June 1, 2017
- FY2016 Earnings Roundup - 3: Price Battle Batters Generic Makers, 3 Majors’ Profit Rate in Single-Digits
May 31, 2017
- FY2016 Earnings Roundup - 2: Entyvio Robust, Xtandi Treads Water as Global Brands Underpin Revenue
May 30, 2017
- FY2016 Earnings Roundup - 1: Japan’s Growth Potential Falters Despite 2.2% CAGR from FY2010
May 29, 2017
BUSINESS
- Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief
January 20, 2025
- Cell and Gene Therapy Market Expected to Top US$20 Billion by 2028: IQVIA
January 20, 2025
- Shionogi Reels in US$375 Million HHS Funding for Preventive COVID-19 Med
January 20, 2025
- Senju Files Mochida-Partnered Dry Eye Drug in Japan
January 20, 2025
- Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket
January 17, 2025
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…